Mizuho analyst Steven Valiquette upgraded Envista (NVST) to Neutral from Underperform with a price target of $24, up from $19. Mizuho’s annual dental industry survey is more positive than prior years, the analyst tells investors in a research note. The firm cites greater earnings visibility for the upgrade of Envista.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVST: